Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

BACKGROUND: The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 μg glycopyrronium (GB)/12 μg formoterol fumarate (FF)/250 μg fluticasone propionate (FP), compared to 50 μg GB co-administered with a fixed dose of 12 μg FF/250 μg FP in subjects wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvi, Sundeep, Balki, Akash, Krishnamurthy, Srikanth, Panchal, Sagar, Patil, Saiprasad, Kodgule, Rahul, Khandagale, Hitesh, Pendse, Amol, Wu, Wen, Rangwala, Shabbir, Tandon, Monika, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311133/
https://www.ncbi.nlm.nih.gov/pubmed/34322547
http://dx.doi.org/10.1183/23120541.00255-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311133/
https://www.ncbi.nlm.nih.gov/pubmed/34322547
http://dx.doi.org/10.1183/23120541.00255-2021

Ejemplares similares